Lilly's retatrutide beats Novo's Ozempic in late-stage trial

What happened

Eli Lilly said retatrutide beat Novo Nordisk's Ozempic in a late-stage trial of nearly 1,300 adults with type 2 diabetes. Retatrutide produced 20% to 21% average weight loss and a 2.2% A1C reduction over 80 weeks, versus 9% and 1.8% for Ozempic.

Confirmed

Global impact / market context

Stronger results could help Eli Lilly win prescriptions and insurer coverage for retatrutide, which means more revenue from obesity and diabetes drugs. Novo Nordisk may face pricing pressure and slower sales growth for Ozempic, affecting its profit outlook and investor positioning in both drugmakers.

Analyst inference

The trial compares two once-weekly injected medicines in the fast-growing obesity and diabetes treatment market. Higher dropout rates on retatrutide, about 5% and 8% versus 3% on Ozempic, could weigh on real-world use and give payers a reason to prefer cheaper options.

Analyst inference

What to watch

1. Eli Lilly plans to present detailed results from the TRANSCEND-T2D-2 Phase 3 analysis at a future medical event and submit them for publication, which could give investors more safety and efficacy data. Confirmed
2. Watch whether Eli Lilly files retatrutide for regulatory approval and whether regulators accept the application, since approval would allow the company to sell the drug and earn revenue. Proposed
3. Track whether insurers and pharmacy benefit managers, which decide which drugs are covered, favor retatrutide over Ozempic; broader coverage would support Lilly's sales and pressure Novo's pricing. Analyst inference

Evidence

• seekingalpha.com